



Packet No.: GNE.3130R1C2

Customer No. 30,313

## INFORMATION DISCLOSURE STATEMENT

Applicant : Ashkenazi, et al.  
App. No : 10/066,273  
Filed : February 1, 2002  
For : SECRETED AND  
TRANSMEMBRANE POLYPEPTIDES  
AND NUCLEIC ACIDS ENCODING  
THE SAME  
Examiner : Chernyshev, Olga  
Art Unit : 1649

## CERTIFICATE OF MAILING

I hereby certify that this correspondence and all  
marked attachments are being deposited with  
the United States Postal Service as first-class  
mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450, on

October 18, 2005

(Date)

AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing thirteen (13) references to be considered by the Examiner. Also enclosed are thirteen (13) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By:

AnneMarie Kaiser  
Registration No. 37,649  
Attorney of Record  
Customer No. 30,313  
(619) 235-8550

Dated: Oct. 18, 2005

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Multiple sheets used when necessary)</i>		Application No.	10/066,273
		Filing Date	February 1, 2002
		First Named Inventor	Avi J. Ashkenazi, et al.
		Art Unit	1649
SHEET 1 OF 1		Examiner	Chernyshev, Olga
		Attorney Docket No.	GNE.3130RIC2

OCT 20 2005  
88  
PATENT AND TRADEMARK OFFICE

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	1	ALON, et al. "Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity." <i>Nature Medicine</i> . 1(10): 1024-1028 (1995).	
	2	BENJAMIN, et al. "Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal." <i>Proc. Natl. Acad. Sci.</i> 94: 8761-8766 (1997).	
	3	ELLIS, et al. "Synopsis of Angiogenesis Inhibitors in Oncology." <i>Oncology</i> . 16(5), Supplement: 14-22 (2002).	
	4	FERRARA, Napoleone. "The role of vascular endothelial growth factor in pathological angiogenesis." <i>Breast Cancer Research and Treatment</i> . 36: 127-137 (1995).	
	5	FIDLER, et al. "Critical Determinants of Neoplastic Angiogenesis." <i>The Cancer Journal</i> . 6(Suppl. 3): S225-S236 (2000).	
	6	JANKNECHT, et al. "Signal integration at the c-fos promoter." <i>Carcinogenesis</i> . 16(3): 443-450 (1995).	
	7	KIRKPATRICK, Peter. "Bevacizumab." <i>Nature</i> . Nature Reviews/Drug Discover. Nature Publishing Group. S8-S9 (May 2005).	
	8	KOLCH, et al. "Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis." <i>Breast Cancer Research and Treatment</i> . 36: 139-155 (1995).	
	9	NEHLS, et al. "Pericyte involvement in capillary sprouting during angiogenesis in situ." <i>Cell Tissue Res.</i> 270: 469-474 (1992).	
	10	RHODIN, et al. "Capillary growth in the mesentery of normal young rats. Intravital video and electron microscope analyses." <i>J. Submicrosc. Cytol. Pathol.</i> 21(1): 1-34 (1989).	
	11	Shima, et al. "The Mouse Gene for Vascular Endothelial Growth Factor." <i>The Journal of Biological Chemistry</i> . 271(7): 3877-3883 (1996).	
	12	Tischer, et al. "The Human Gene for Vascular Endothelial Growth Factor." <i>The Journal of Biological Chemistry</i> . 266(18): 11947-11954 (1991).	
	13	Willett, et al. "Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer." <i>Nature Medicine</i> . 10(2): 145-147 (2004).	

2001129  
101805

Examiner Signature	Date Considered
<b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.